Evidence map›Paper›PMID 30642048›Full record

ArticleToxins2019

Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays.

Bruna Xavier, Rafaela Ferreira Perobelli, Maurício Elesbão Walter, Francielle Santos da Silva, Sérgio Luiz Dalmora

Abstract read
In one paragraph

Article in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. IMPROVING THE ACCURACY OF BOTULINUM TOXIN INJECTIONS CANNOT RELY ON SYRINGE DEVICES.The Journal of clinical and aesthetic dermatology · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bruna XavierPostgraduate Programme in Pharmaceutical Sciences; Federal University of Santa Maria, Santa Maria 97105-900, Brazil. bxavier28@gmail.com.
Rafaela Ferreira PerobelliPostgraduate Programme in Pharmaceutical Sciences; Federal University of Santa Maria, Santa Maria 97105-900, Brazil. rafaelaperobelli@gmail.com.
Maurício Elesbão WalterPostgraduate Programme in Pharmaceutical Sciences; Federal University of Santa Maria, Santa Maria 97105-900, Brazil. mauricio.walter13@gmail.com.
Francielle Santos da SilvaPostgraduate Programme in Pharmaceutical Sciences; Federal University of Santa Maria, Santa Maria 97105-900, Brazil. fransantos.biomed@gmail.com.
Sérgio Luiz DalmoraIndustrial Pharmacy Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil. sdalmora@terra.com.br.ORCID 0000-0003-0103-4416

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum neurotoxin type-A (BoNTA) is one of the seven different serotypes (A to G) produced by Clostridium botulinum. A stability-indicating size-exclusion chromatography (SEC) method was developed and validated, and the specificity was confirmed by forced degradation study, interference of the excipients, and peaks purity. The method was applied to assess the content and high-molecular-weight (HMW) forms of BoNTA in biopharmaceutical products, and the results were compared with those of the LD

Indexed as

AnimalsBiological AssayBotulinum Toxins, Type ACell LineCell SurvivalChromatography, GelChromatography, LiquidChromatography, Reverse-PhaseFemaleHumansLethal Dose 50MiceReproducibility of ResultsBotulinum Toxins, Type Abotulinum neurotoxin type ALD50 mouse bioassayreversed-phase chromatographysize-exclusion chromatographyT−47D cell culture

Identifiers

PMID30642048
PMCPMC6356430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.